Genetic risk variants upstream of the SOX17 promoter impair transcription factor binding, leading to reduced SOX17 expression in human PAECs (HPAECs) and contributing to endothelial dysfunction in PAH. The gene discussed is SOX17; the disease is pulmonary arterial hypertension.